1. Protective role for kidney TREM2 high macrophages in obesity- and diabetes-induced kidney injury.
- Author
-
Subramanian A, Vernon KA, Zhou Y, Marshall JL, Alimova M, Arevalo C, Zhang F, Slyper M, Waldman J, Montesinos MS, Dionne D, Nguyen LT, Cuoco MS, Dubinsky D, Purnell J, Keller K, Sturner SH, Grinkevich E, Ghoshal A, Kotek A, Trivioli G, Richoz N, Humphrey MB, Darby IG, Miller SJ, Xu Y, Weins A, Chloe-Villani A, Chang SL, Kretzler M, Rosenblatt-Rosen O, Shaw JL, Zimmerman KA, Clatworthy MR, Regev A, and Greka A
- Subjects
- Animals, Mice, Humans, Male, Mice, Inbred C57BL, Female, Receptors, Immunologic metabolism, Receptors, Immunologic genetics, Membrane Glycoproteins metabolism, Membrane Glycoproteins genetics, Macrophages metabolism, Obesity metabolism, Obesity pathology, Obesity complications, Diabetic Nephropathies metabolism, Diabetic Nephropathies pathology, Kidney pathology, Kidney metabolism, Diet, High-Fat, Mice, Knockout
- Abstract
Diabetic kidney disease (DKD), the most common cause of kidney failure, is a frequent complication of diabetes and obesity, and yet to date, treatments to halt its progression are lacking. We analyze kidney single-cell transcriptomic profiles from DKD patients and two DKD mouse models at multiple time points along disease progression-high-fat diet (HFD)-fed mice aged to 90-100 weeks and BTBR ob/ob mice (a genetic model)-and report an expanding population of macrophages with high expression of triggering receptor expressed on myeloid cells 2 (TREM2) in HFD-fed mice. TREM2
high macrophages are enriched in obese and diabetic patients, in contrast to hypertensive patients or healthy controls in an independent validation cohort. Trem2 knockout mice on an HFD have worsening kidney filter damage and increased tubular epithelial cell injury, all signs of worsening DKD. Together, our studies suggest that strategies to enhance kidney TREM2high macrophages may provide therapeutic benefits for DKD., Competing Interests: Declaration of interests A.Greka has a financial interest in Sail Bio, which was reviewed and is managed by Brigham and Women’s Hospital, Mass General Brigham (MGB), and the Broad Institute of MIT and Harvard in accordance with their conflict of interest policies. K.A.V. is an employee and shareholder of Q32 Bio, Inc. J.L.S. is an equity holder of Magnetic Ventures. A.R. is a cofounder and equity holder of Celsius Therapeutics and equity holder of Immunitas and, until August 2020, was an SAB member of Thermo Fisher Scientific, Syros Pharmaceuticals, Neogene Therapeutics, and Asimov. A.R. is an employee of Genentech, Inc. O.R.-R is an employee of Genentech, Inc. O.R.-R. is a coinventor on patent applications filed by the Broad Institute related to single-cell genomics., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF